Treg cells expressing CCR4 were shown to be attracted to CCL22 released by myeloid cells in ovarian cancer, and the anti-CCR4 mAb Mogamulizumab effectively elicited anticancer responses via the depletion of effector Treg cells in solid tumors [8]. This evidence concerns the gene CCR4 and ovarian cancer.